Unique ID issued by UMIN | UMIN000005601 |
---|---|
Receipt number | R000006618 |
Scientific Title | Effect of the Combination of varsartan with HCTZ on circadian BP rhythm |
Date of disclosure of the study information | 2011/05/23 |
Last modified on | 2016/10/16 10:52:31 |
Effect of the Combination of varsartan with HCTZ on circadian BP rhythm
Varsartan & HCTZ
Effect of the Combination of varsartan with HCTZ on circadian BP rhythm
Varsartan & HCTZ
Japan |
Chronic Kidney Disease (CKD)
Nephrology |
Others
NO
To investigate whether or not the additional medication of diuretics to ARB can restore non-dipper circadian BP rhythm.
Efficacy
Exploratory
Pragmatic
Not applicable
Decrease in the night/day ratio ofmean arterial pressure (MAP)
office BP, night/day ratios of natriuresis and albuminuria, urinary angiotensinogen excretion rate, plasma catecholamines
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
additional medication of HCTZ (12.5mg/d) to valsartan (80mg/d, once in the morning) for 2 months
20 | years-old | <= |
Not applicable |
Male and Female
1. received medical care at Nagoya City University Hospital; age of 20 or more y
2. CKD criteria based on K/DOQI
3. previous treatment with valsartan (80mg/d) for 2 months or more, office BP >130/80 on at least one occasion
4. documented informed concent
1. previous treatment with ARB, other than valsartan, or diuretics 2 months before enrollment
2. contraindication to valsartan or HCTZ (history of allergic reaction to them, bilateral renal artery stenosis)
3. presence or possibility of pregnancy
4. HbA1c 9.0 or more %
5. GOT >100, or GPT >85
6. endocrine hypertension
7. accelerated o r malignant hypertension (progressive renal dysfunction with diastolic BP of >120-130 mmHg
8. serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases
9. nephrotic syndrome (serum albumin <2.5 g/dl)
10. patients under hemodialysis therapy
11. any reason for ineligibility suggested by the attending doctor
30
1st name | |
Middle name | |
Last name | Michio Fukuda |
Nagoya City University Graduate School of Medical Sciences
Cardio-Renal Medicine and Hypertension
1 Kawasumi, Mizuho-ku, Nagoya 467-8601, Japan
81-52-853-8221
m-fukuda@med.nagoya-cu.ac.jp
1st name | |
Middle name | |
Last name | Michio Fukuda |
Nagoya City University Graduate School of Medical Sciences
Cardio-Renal Medicine and Hypertension
1 Kawasumi, Mizuho-ku, Nagoya 467-8601, Japan
81-52-853-8221
m-fukuda@med.nagoya-cu.ac.jp
Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
None
Self funding
Japan
NO
名古屋市立大学病院 Nagoya City University Hospital (愛知県)
2011 | Year | 05 | Month | 23 | Day |
http://www.med.nagoya-cu.ac.jp/cr.dir/
Published
Of the 25 eligible patients, one had excess BP reduction during add-on HCTZ therapy and another was judged as excessive urine collection, and they were excluded from the study.
Lower Na balance was produced by add-on HCTZ to ARB treatment without an increase of intrarenal renin-angiotensin system activity, leading to restoration of nocturnal hypertension.
J Renin Angiotensin Aldosterone Syst. 2016 Jun 9;17(2):1470320316652032
Completed
2010 | Year | 12 | Month | 02 | Day |
2011 | Year | 05 | Month | 01 | Day |
2015 | Year | 09 | Month | 01 | Day |
2015 | Year | 12 | Month | 31 | Day |
2015 | Year | 12 | Month | 31 | Day |
2015 | Year | 12 | Month | 31 | Day |
2011 | Year | 05 | Month | 15 | Day |
2016 | Year | 10 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006618